KLRK1 and neoplasm: Besides inducing CAR–NK cytotoxicity towards antigens expressed by various tumor types, NKG2D–CAR–NKs have been designed by Parihar and colleagues to ameliorate NK cell persistence within the immunosuppressive TME by eradicating MDSCs [164].